7.83 (-%)
As of Dec 06, 2024
Source:
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (“ABC”) Platform, for retinal medicines. Our goal is to prevent and treat the major causes of blindness by developing and commercializing next-generation therapeutics to address multiple unmet needs on the spectrum of retinal diseases.
Country | United States |
Headquarters | palo alto, california |
Phone Number | (650) 281-0850 |
Industry | manufacturing |
CEO | Victor Perlroth |
Website | kodiak.com |